{"id":3996,"date":"2025-05-13T10:30:56","date_gmt":"2025-05-13T07:30:56","guid":{"rendered":"https:\/\/relinvestmentsgroup.com\/?p=3996"},"modified":"2025-05-14T10:36:19","modified_gmt":"2025-05-14T07:36:19","slug":"bain-capital-planiruet-priobresti-kompaniyu-v-sfere-zdravoohraneniya-za-10-mlrd-dollarov-s-eksklyuzivnym-predlozheniem-o-pokupke-pci-pharma","status":"publish","type":"post","link":"https:\/\/relinvestmentsgroup.com\/en\/bain-capital-planiruet-priobresti-kompaniyu-v-sfere-zdravoohraneniya-za-10-mlrd-dollarov-s-eksklyuzivnym-predlozheniem-o-pokupke-pci-pharma\/","title":{"rendered":"Bain Capital eyes $10bn healthcare buyout with exclusive bid for PCI Pharma"},"content":{"rendered":"<p><\/p>\n<p class=\"p1\">Bain Capital is in advanced negotiations to acquire a majority stake in PCI Pharma Services in a potential $10bn deal.<span class=\"Apple-converted-space\">\u00a0<\/span><\/p>\n<p class=\"p1\">The acquisition would represent one of the largest private equity transactions of 2025 and mark a major expansion for Bain in the healthcare sector.<\/p>\n<p class=\"p1\">The proposed deal values Philadelphia-headquartered PCI Pharma\u2014including debt\u2014at over $10bn. Current backers Kohlberg &amp; Co, Mubadala Investment Co, and Partners Group are involved in the talks, which remain subject to market conditions and have not yet been finalised.<\/p>\n<p class=\"p1\">Bain is expected to bring in sovereign wealth funds and other major institutional investors to co-invest in the deal. The firm has an established track record in healthcare and previously partnered with Mubadala on a minority investment in Zelis Healthcare Corp in 2023.<\/p>\n<p class=\"p1\">PCI provides mission-critical pharmaceutical packaging services, including sterile fill-finish and pre-filled syringe assembly for high-demand drugs such as GLP-1-based obesity treatments like Wegovy. Its role in this rapidly growing sector has made it an attractive acquisition target for both strategic and financial buyers.<\/p>\n<p class=\"p1\">Kohlberg acquired a majority stake in PCI in 2020 from Partners Group, with Mubadala joining as a minority investor. Since then, the company has expanded significantly across its global operations and customer base.<\/p>\n<p class=\"p1\">The potential buyout is being supported by a private credit financing package led by Blue Owl Capital, which includes a $3bn unitranche facility and an additional delayed-draw term loan of over $1bn.<\/p>\n<p><\/p>","protected":false},"excerpt":{"rendered":"<p>Bain Capital is in advanced negotiations to acquire a majority stake in PCI Pharma Services in a potential $10bn deal.\u00a0 The acquisition would represent one of the largest private equity transactions of 2025 and mark a major expansion for Bain in the healthcare sector. The proposed deal values Philadelphia-headquartered PCI Pharma\u2014including debt\u2014at over $10bn. Current [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":3997,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-3996","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-bez-rubriki"],"featured_image_src":{"landsacpe":["https:\/\/relinvestmentsgroup.com\/wp-content\/uploads\/2025\/05\/Money-66-1-1140x445.webp",1140,445,true],"list":["https:\/\/relinvestmentsgroup.com\/wp-content\/uploads\/2025\/05\/Money-66-1-463x348.webp",463,348,true],"medium":["https:\/\/relinvestmentsgroup.com\/wp-content\/uploads\/2025\/05\/Money-66-1-300x200.webp",300,200,true],"full":["https:\/\/relinvestmentsgroup.com\/wp-content\/uploads\/2025\/05\/Money-66-1.webp",1254,836,false]},"_links":{"self":[{"href":"https:\/\/relinvestmentsgroup.com\/en\/wp-json\/wp\/v2\/posts\/3996","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/relinvestmentsgroup.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/relinvestmentsgroup.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/relinvestmentsgroup.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/relinvestmentsgroup.com\/en\/wp-json\/wp\/v2\/comments?post=3996"}],"version-history":[{"count":1,"href":"https:\/\/relinvestmentsgroup.com\/en\/wp-json\/wp\/v2\/posts\/3996\/revisions"}],"predecessor-version":[{"id":3998,"href":"https:\/\/relinvestmentsgroup.com\/en\/wp-json\/wp\/v2\/posts\/3996\/revisions\/3998"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/relinvestmentsgroup.com\/en\/wp-json\/wp\/v2\/media\/3997"}],"wp:attachment":[{"href":"https:\/\/relinvestmentsgroup.com\/en\/wp-json\/wp\/v2\/media?parent=3996"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/relinvestmentsgroup.com\/en\/wp-json\/wp\/v2\/categories?post=3996"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/relinvestmentsgroup.com\/en\/wp-json\/wp\/v2\/tags?post=3996"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}